Payment overview · 2025
General Payments
$386.86
14 reported records · 11 companies
Healthcare provider profile · identity verified
Alan Stuart Bock, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OKLAHOMA CITY, OK · NPI 1013025923
Verified facts
What the public records show
CMS Open Payments records show Alan Stuart Bock, M.D. received $386.86 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $140.79 | 36.4% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $55.89 | 14.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $39.67 | 10.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.70 | 6.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.62 | 6.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.96 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.53 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.88 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.46 | 4.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.13 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.23 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.86 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.77 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $55.89 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 156 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 105 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 23 |
| Lisinopril | Lisinopril | 86 | 23 |
| Gabapentin | Gabapentin | 68 | 21 |
| Valsartan | Valsartan | 67 | 17 |
| Sertraline Hcl | Sertraline Hcl | 65 | 16 |
| Losartan Potassium | Losartan Potassium | 63 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 14 |
| Ozempic | Semaglutide | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 17 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 15 |
| Temazepam | Temazepam | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 11 |
| Jardiance | Empagliflozin | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Furosemide | Furosemide | 42 | 14 |
| Alprazolam | Alprazolam | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 31 |
| Potassium Chloride | Potassium Chloride | 38 | 13 |
| Eliquis | Apixaban | 37 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Omeprazole | Omeprazole | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 22 |
| Prednisone | Prednisone | 28 | 25 |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Metformin Hcl | Metformin Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 13 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Clonazepam | Clonazepam | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.86 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FARXIGA, GARDASIL 9, GEMTESA, Hillrom - Monarch Airway Clearance System, JARDIANCE, Korlym, NURTEC ODT, REXULTI, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error